Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

Article Details

Citation
Copy to clipboard

Wu J, Zhang M, Liu D

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.

PubMed ID
26957112 [ View in PubMed
]
Abstract

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.

DrugBank Data that Cites this Article

Drugs